10:14 AM EST - Bausch Health Companies Inc. : And its dermatology business, Ortho Dermatologics, one of the largest dermatology health care businesses in the world, today announced the presentation of nine posters during the virtual Fall Clinical Dermatology Conference, which takes place Oct. 29 - Nov. 1 . The presentations will feature new post hoc analyses on ARAZLO™ (tazarotene) Lotion, 0.045%, DUOBRII® (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, and SILIQ® (brodalumab) injection 210 mg/1.5 ml, as well as pediatric data on JUBLIA® (efinaconazole) topical solution, 10%. Bausch Health Companies Inc.
shares T.BHC are trading down $0.26 at $23.86.
